Current and potential epigenetic targets in multiple myeloma

Epigenomics

Volumn 6, Issue 2, 2014, Pages 215-228

  Pawlyn, Charlotte ^a   Kaiser, Martin F ^a   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

bromodomain inhibitor; chromatin; DNA methyltransferase inhibitor; histone deacetylase inhibitor; histone demethylase inhibitor; histone methyltransferase inhibitor; multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; BROMODOMAIN INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; MYC PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE;

B LYMPHOCYTE; CANCER PROGNOSIS; CANCER THERAPY; CELL MATURATION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE MYC; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; VDJ RECOMBINATION; ACETYLATION; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS;

ACETYLATION; B-LYMPHOCYTES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MULTIPLE MYELOMA;

EID: 84900413733     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.12     Document Type: Review

References (106)

1. Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354(13), 1362-1369 (2006).
2. Kyle RA, Remstein ED, Therneau TM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582-2590 (2007). (Pubitemid 46961003)
3. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12(5), 335-348 (2012).
4. Walker BA, Wardell CP, Melchor L et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28(2), 384-390 (2013).
5. Gandhi AK, Kang J, Havens CG et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4. Br. J. Haematol. doi:10.1111/bjh.12708 (2013) (Epub ahead of print).
6. Lu G, Middleton RE, Sun H et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168), 305-309 (2014).
7. Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11), 4569-4575 (2003). (Pubitemid 36857829)
8. Gertz MA, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 106(8), 2837-2840 (2005). (Pubitemid 41510761)
9. Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br. J. Haematol. 125(1), 64-68 (2004). (Pubitemid 38453279)
10. Moreau P, Facon T, Leleu X et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100(5), 1579-1583 (2002). (Pubitemid 34925131)
11. Boyd KD, Ross FM, Chiecchio L et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS. analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26(2), 349-355 (2012).
12. Boyd KD, Ross FM, Tapper WJ et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 50(10), 765-774 (2011).
13. Hanamura I, Stewart JP, Huang Y et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108(5), 1724-1732 (2006). (Pubitemid 44316143)
14. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105(1), 358-360 (2005). (Pubitemid 40053104)
15. Walker BA, Leone PE, Chiecchio L et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116(15), e56-e65 (2010).
16. Decaux O, Lode L, Magrangeas F et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J. Clin. Oncol. 26(29), 4798-4805 (2008).
17. Shaughnessy JD Jr, Zhan F, Burington BE et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6), 2276-2284 (2007). (Pubitemid 46425864)
18. Mikhael JR, Dingli D, Roy V et al. Management of newly diagnosed symptomatic multiple myeloma. updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88(4), 360-376 (2013).
19. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat. Rev. Immunol. 11(4), 251-263 (2011).
20. Shaknovich R, Cerchietti L, Tsikitas L et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood 118(13), 3559-3569 (2011).
21. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8(5), 463-470 (2007). (Pubitemid 46605911)
22. Decker T, Pasca Di Magliano M, Mcmanus S et al. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity 30(4), 508-520 (2009).
23. Li G, Zan H, Xu Z, Casali P. Epigenetics of the antibody response. Trends Immunol. 34(9), 460-470 (2013).
24. Ramachandrareddy H, Bouska A, Shen Y et al. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells. Proc. Natl Acad. Sci. USA 107(26), 11930-11935 (2010).
25. Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 5(3), 299-308 (2004). (Pubitemid 38332127)
26. COSMIC. Catalogue of somatic mutations in cancer.http://cancer.sanger.ac. uk/cancergenome/projects/cosmic
27. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150(1), 12-27 (2012).
28. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007). (Pubitemid 46802390)
29. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
30. Keats JJ, Reiman T, Maxwell CA et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101(4), 1520-1529 (2003). (Pubitemid 36182529)
31. Zhou P, Wu LL, Wu KM et al. Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma. Pathol. Oncol. Res. 19(2), 303-309 (2013).
32. Xiao M, Yang S, Chen J et al. Overexpression of MMSET in endometrial cancer. a clinicopathologic study. J. Surg. Oncol. 107(4), 428-432 (2013).
33. Hudlebusch HR, Skotte J, Santoni-Rugiu E et al. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res. 71(12), 4226-4235 (2011).
34. Oyer JA, Huang X, Zheng Y et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia 28(1), 198-192 (2014).
35. Jaffe JD, Wang Y, Chan HM et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45(11), 1386-1391 (2013).
36. Nimura K, Ura K, Shiratori H et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460(7252), 287-291 (2009).
37. Kim JY, Kee HJ, Choe NW et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol. Cell Biol. 28(6), 2023-2034 (2008).
38. Marango J, Shimoyama M, Nishio H et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111(6), 3145-3154 (2008).
39. Pei H, Zhang L, Luo K et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470(7332), 124-128 (2011).
40. Martinez-Garcia E, Popovic R, Min DJ et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117(1), 211-220 (2011).
41. Kuo AJ, Cheung P, Chen K et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44(4), 609-620 (2011).
42. Hudlebusch HR, Theilgaard-Monch K, Lodahl M, Johnsen HE, Rasmussen T. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br. J. Haematol. 130(5), 700-708 (2005). (Pubitemid 43906642)
43. Ezponda T, Popovic R, Shah MY et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 32(23), 2882-2890 (2013).
44. Brito JL, Walker B, Jenner M et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 94(1), 78-86 (2009).
45. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10(5), 295-304 (2009).
46. Walker BA, Wardell CP, Chiecchio L et al Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117(2), 553-562 (2011).
47. Asangani IA, Ateeq B, Cao Q et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 49(1), 80-93 (2013).
48. Bernt KM, Zhu N, Sinha AU et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20(1), 66-78 (2011).
49. Daigle SR, Olhava EJ, Therkelsen CA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122(6), 1017-1025 (2013).
50. Huang Z, Wu H, Chuai S et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res. 73(20), 6277-6288 (2013).
51. Daigle SR, Olhava EJ, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53-65 (2011).
52. Kuhn M, Hadler M, Daigle SR et al. Myeloid leukemia cells with MLL partial tandem duplication are sensitive to pharmacological inhibition of the H3K79 methyltransferase DOT1L. Blood 122(21), 1256 (2013).
53. Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339), 467-472 (2011).
54. Cavo M, Terragna C, Renzulli M et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma. low complete remission rate and short duration of remission. J. Clin. Oncol. 24(3), e4-e5 (2006).
55. Pineda-Roman M, Zangari M, Haessler J et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br. J. Haematol. 140(6), 625-634 (2008). (Pubitemid 351300910)
56. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
57. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28(30), 4630-4634 (2010).
58. Avet-Loiseau H, Soulier J, Fermand JP et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 24(3), 623-628 (2010).
59. Kapoor P, Kumar S, Fonseca R et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114(3), 518-521 (2009).
60. Mccabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427), 108-112 (2012).
61. Knutson SK, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012).
62. Qi W, Chan H, Teng L et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52), 21360-21365 (2012).
63. Konze KD, Ma A, Li F et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8(6), 1324-1334 (2013).
64. Garapaty-Rao S, Nasveschuk C, Gagnon A et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20(11), 1329-1339 (2013).
65. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24(41), 6269-6280 (2005). (Pubitemid 43080050)
66. Kalushkova A, Fryknas M, Lemaire M et al. Polycomb target genes are silenced in multiple myeloma. PLoS ONE 5(7), e11483 (2010).
67. Van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009).
68. Schenk T, Chen WC, Gollner S et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18(4), 605-611 (2012).
69. Krejci J, Harnicarova A, Streitova D et al. Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation. Leuk. Res. 33(11), 1490-1498 (2009).
70. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338(1), 17-31 (2004). (Pubitemid 38429783)
71. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 62(1), 18-34 (2010).
72. Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834-840 (2009).
73. Ocio EM, San Miguel JF. The DAC system and associations with multiple myeloma. Invest. New drugs 28(Suppl. 1), S28-S35 (2010).
74. Dimopoulos M, Siegel DS, Lonial S et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 14(11), 1129-1140 (2013).
75. Richardson PG, Schlossman RL, Alsina M et al. PANORAMA 2. panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14), 2331-2337 (2013).
76. Offidani M, Polloni C, Cavallo F et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk. Lymphoma 53(9), 1722-1727 (2012).
77. Harrison SJ, Quach H, Link E et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118(24), 6274-6283 (2011).
78. Siegel DS, Dimopoulos MA, Yoon SS et al. VANTAGE 095: final results from a global, single-arm, Phase 2b trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients. Presented at: European Society of Haematology Annual Meeting, Amsterdam, The Netherlands, 14-17 June 2012.
79. Clinical Trials. gov.www.clinicaltrials.gov
80. Santo L, Hideshima T, Kung AL et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11), 2579-2589 (2012).
81. Banerji U, Van Doorn L, Papadatos-Pastos D et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin. Cancer Res. 18(9), 2687-2694 (2012).
82. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2), 336-342 (2011).
83. Richardson P, Mitsiades C, Colson K et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 49(3), 502-507 (2008). (Pubitemid 351298334)
84. Wolf JL, Siegel D, Goldschmidt H et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma 53(9), 1820-1823 (2012).
85. Richardson PG, Schlossman RL, Alsina M et al. PANORAMA 2. panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14), 2331-2337 (2013).
86. Smith EM, Zhang L, Walker BA et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFkB signalling pathway. Oncotarget (2013) (In Press).
87. Ocio EM, Vilanova D, Atadja P et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95(5), 794-803 (2010).
88. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29 (2011).
89. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011).
90. Chng WJ, Huang GF, Chung TH et al. Clinical and biological implications of MYC activation. a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25(6), 1026-1035 (2011).
91. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood 120(12), 2450-2453 (2012).
92. Chesi M, Robbiani DF, Sebag M et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13(2), 167-180 (2008). (Pubitemid 351163163)
93. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J. Natl Cancer Inst. (39), 25-31 (2008).
94. Walker BA, Wardell C, Brioli A et al. Translocations at 8q24 Recruit super-enhancers resulting in over-expression of myc and poor prognosis in myeloma patients. Blood Cancer J. (In Press).
95. Dawson MA, Prinjha RK, Dittmann A et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370), 529-533 (2011).
96. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13(7), 484-492 (2012).
97. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 70(17), 6934-6944 (2010).
98. Kaiser MF, Johnson DC, Wu P et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood 122(2), 219-226 (2013).
99. Tsai HC, Li H, Van Neste L et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3), 430-446 (2012).
100. Pichiorri F, Suh SS, Rocci A et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18(4), 367-381 (2010).
101. Moreaux J, Reme T, Leonard W et al. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol. Cancer Ther. 11(12), 2685-2692 (2012).
102. Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine. Br. J. Haematol. 164(4), 613-616 (2013).
103. Kiziltepe T, Hideshima T, Catley L et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol. Cancer Ther. 6(6), 1718-1727 (2007). (Pubitemid 46954048)
104. Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 93(6), 860-869 (2008). (Pubitemid 351821722)
105. Chen G, Wang Y, Huang H et al. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur. J. Haematol. 82(3), 176-183 (2009).
106. Toor AA, Payne KK, Chung HM et al. Epigenetic induction of adaptive immune response in multiple myeloma. sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. Br. J. Haematol. 158(6), 700-711 (2012).